Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclin-dependent kinase inhibitors - Cyclacel Pharmaceuticals

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Cyclacel Pharmaceuticals

Alternative Names: 2-Anilino-4-(thiazol-5-yl)-pyrimidine - Cyclacel Pharmaceuticals; CCT-68127; CYC 11056; CYC400 series - Cyclacel Pharmaceuticals; Second-generation CDK inhibitors - Cyclacel Pharmaceuticals; Tri-substituted purines - Cyclacel Pharmaceuticals

Latest Information Update: 28 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Purines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuroblastoma
  • No development reported Acute myeloid leukaemia; Cancer; Glomerulonephritis; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 May 2019 No recent reports of development identified for preclinical development in Cancer in United Kingdom (IV)
  • 28 Oct 2018 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (PO)
  • 28 Oct 2018 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top